Bioextrax - Public Comps and Valuation Multiples

Bioextrax Overview

About Bioextrax

Bioextrax AB is engaged in the development and production of bio-plastics granules, organic hydrolyzed protein, and keratin fibers.

Founded

2014

HQ

Employees

n/a

Website

bioextrax.com

Sectors

Environmental & Facilities Services

Financials

LTM Revenue $0.1M

LTM EBITDA -$1.8M

EV

$14.3M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Bioextrax Financials

As of January 2026, Bioextrax reported last 12-month revenue of $0.1M and EBITDA of -$1.8M.

In the same period, Bioextrax generated $5K in LTM gross profit and -$2.0M in net income.

See Bioextrax valuation multiples based on analyst estimates

Bioextrax P&L

In the most recent fiscal year, Bioextrax reported revenue of $0.1M and EBITDA of -$1.8M.

Bioextrax expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Bioextrax valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$0.1M	XXX	$0.1M	XXX	XXX	XXX
Gross Profit	$5K	XXX	-$0.1M	XXX	XXX	XXX
Gross Margin	5%	XXX	-178%	XXX	XXX	XXX
EBITDA	-$1.8M	XXX	-$1.8M	XXX	XXX	XXX
EBITDA Margin	-1551%	XXX	-3141%	XXX	XXX	XXX
EBIT	-$2.0M	XXX	-$2.0M	XXX	XXX	XXX
EBIT Margin	-1660%	XXX	-3406%	XXX	XXX	XXX
Net Profit	-$2.0M	XXX	-$1.9M	XXX	XXX	XXX
Net Margin	-1651%	XXX	-3367%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Bioextrax including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $0.1M. EBITDA for the last twelve months was -$1.8M. In the most recent fiscal year, Bioextrax achieved $0.1M in revenue and -$1.8M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$0.1M	Analyst estimates available to subscribers	$0.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$5K	Analyst estimates available to subscribers	-$0.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	4.6% gross margin	Analyst estimates available to subscribers	-177.7% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$1.8M	Analyst estimates available to subscribers	-$1.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	-1550.9% EBITDA margin	Analyst estimates available to subscribers	-3141.2% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$2.0M	Analyst estimates available to subscribers	-$2.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-1660.1% EBIT margin	Analyst estimates available to subscribers	-3405.6% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$2.0M	Analyst estimates available to subscribers	-$1.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-1650.6% net profit margin	Analyst estimates available to subscribers	-3366.6% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Bioextrax

This financial data table provides comprehensive performance metrics for Bioextrax, a company based in Sweden. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Bioextrax generated $0.1M in revenue over the last twelve months.
The company achieved -$1.8M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $5K.
Net income over the last twelve months reached -$2.0M.

Fiscal Year Performance

In the most recent fiscal year, Bioextrax reported $0.1M in total revenue.
Fiscal year EBITDA was -$1.8M.
The company maintained a gross profit margin of -177.7% in the most recent fiscal year.
EBITDA margin for the fiscal year was -3141.2%.
Net profit margin reached -3366.6% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Bioextrax. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Bioextrax Stock Performance

Bioextrax has current market cap of SEK 135M (or $15.2M), and EV of SEK 127M (or $14.3M).

Market Cap Evolution

Bioextrax Stock Data

As of February 25, 2026, Bioextrax's stock price is SEK 3 (or $0).

See Bioextrax trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$14.3M	$15.2M	XXX	XXX	XXX	XXX	$-0.02

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Bioextrax Valuation Multiples

Bioextrax's trades at 120.7x EV/Revenue multiple, and -7.8x EV/EBITDA.

See valuation multiples for Bioextrax and 15K+ public comps

Bioextrax Financial Valuation Multiples

As of February 25, 2026, Bioextrax has market cap of $15.2M and EV of $14.3M.

Equity research analysts estimate Bioextrax's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Bioextrax has a P/E ratio of -7.8x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$15.2M	XXX	$15.2M	XXX	XXX	XXX
EV (current)	$14.3M	XXX	$14.3M	XXX	XXX	XXX
EV/Revenue	120.7x	XXX	120.7x	XXX	XXX	XXX
EV/EBITDA	-7.8x	XXX	-7.8x	XXX	XXX	XXX
EV/EBIT	-7.3x	XXX	-7.3x	XXX	XXX	XXX
EV/Gross Profit	2597.3x	XXX	n/a	XXX	XXX	XXX
P/E	-7.8x	XXX	-7.8x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-6.7x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Bioextrax Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Bioextrax Margins & Growth Rates

Bioextrax's last 12 month revenue growth is 406%

Bioextrax's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Bioextrax's rule of 40 is -598% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Bioextrax's rule of X is -535% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Bioextrax and other 15K+ public comps

Bioextrax Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	406%	XXX	322%	XXX	XXX	XXX
EBITDA Margin	-1551%	XXX	-1551%	XXX	XXX	XXX
EBITDA Growth	2%	XXX	n/a	XXX	XXX	XXX
Rule of 40	-598%	XXX	-1144%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	-535%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	3228%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial